How Gastric Bypass Changes Your Brain's Response to Food — And GLP-1 Is the Key
After gastric bypass surgery, elevated GLP-1 levels directly reduce the brain's reward response to food, and blocking GLP-1 reverses this effect.
Quick Facts
What This Study Found
After Roux-en-Y gastric bypass (RYGB), GLP-1 levels were significantly elevated, and brain responses to food cues were reduced in key reward and taste-processing regions. Using the GLP-1 receptor blocker exendin 9-39, the researchers demonstrated that blocking GLP-1 signaling reversed these brain changes — restoring the heightened food-cue responses that existed before surgery. This provides direct evidence that GLP-1 mediates the reduced food motivation seen after bariatric surgery.
Specifically, after RYGB, brain activation decreased in the rolandic operculum and caudate nucleus when viewing food pictures (P=0.03) and in the insula when tasting palatable food (P=0.003). Blocking GLP-1 receptors with exendin 9-39 reversed the reduced activation in the caudate nucleus (P=0.02) and insula (P=0.002).
Key Numbers
n=10 · GLP-1 levels significantly elevated post-RYGB · P=0.03 reduced brain activation to food pictures · P=0.003 reduced insula response to palatable food · P=0.02 and P=0.002 for GLP-1 blockade reversal effects
How They Did This
Crossover study in 10 women before and after RYGB surgery. Each participant underwent functional MRI brain scans while viewing food pictures and tasting chocolate milk under two conditions: with exendin 9-39 (a GLP-1 receptor blocker) and with placebo. Comparing brain activation patterns across these conditions before and after surgery isolated the specific contribution of GLP-1 to post-surgical changes in food-related brain activity.
Why This Research Matters
This study helps explain why people lose so much weight after gastric bypass — it's not just about a smaller stomach. The surgery dramatically increases GLP-1 production, which changes how the brain responds to food. This is the same hormone that drugs like semaglutide and tirzepatide mimic, providing a biological explanation for why GLP-1 medications reduce food cravings in a similar way to bariatric surgery.
The Bigger Picture
This study bridges two major trends in obesity treatment: bariatric surgery and GLP-1 medications. By showing that gastric bypass works partly through the same GLP-1 pathway that drugs like semaglutide target, it suggests these treatments share a common mechanism — changing how the brain processes food rewards. This helps explain the often-reported experience of patients on GLP-1 drugs saying they simply 'stop thinking about food.'
What This Study Doesn't Tell Us
Very small sample size of only 10 women limits generalizability. All-female cohort means results may not apply to men. The study design is complex with multiple comparisons, increasing the risk of false positive findings. Brain imaging studies capture neural activity but don't directly measure behavior or food intake. Short-term assessments may not reflect long-term effects.
Questions This Raises
- ?Do GLP-1 medications produce the same brain activation changes as bariatric surgery, or do they work through slightly different neural pathways?
- ?Would these brain changes persist long-term after surgery, or does the brain eventually adapt back?
- ?Could measuring brain responses to food cues predict which patients will have the best outcomes from GLP-1 therapy?
Trust & Context
- Key Stat:
- GLP-1 blockade reversed brain changes When researchers blocked GLP-1 receptors after gastric bypass, the brain's reduced food-cue responses came back — proving GLP-1 mediates the surgical effect on appetite.
- Evidence Grade:
- This is a well-designed mechanistic study using a crossover approach with a GLP-1 blocker, but the sample size of only 10 women is very small. The findings are compelling and hypothesis-generating but need replication in larger, more diverse populations.
- Study Age:
- Published in 2017 in Diabetes Care, this study predates the widespread use of GLP-1 medications for weight loss but its mechanistic insights about GLP-1's brain effects remain highly relevant to understanding how these drugs work.
- Original Title:
- Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.
- Published In:
- Diabetes care, 40(11), 1522-1529 (2017)
- Authors:
- Ten Kulve, Jennifer S, Veltman, Dick J, Gerdes, Victor E A, van Bloemendaal, Liselotte, Barkhof, Frederik, Deacon, Carolyn F, Holst, Jens J, Drent, Madeleine L, Diamant, Michaela, IJzerman, Richard G
- Database ID:
- RPEP-03494
Evidence Hierarchy
Frequently Asked Questions
Does this explain why GLP-1 drugs like Ozempic reduce food cravings?
Yes, this study provides a biological mechanism. It shows that GLP-1 directly reduces how the brain's reward centers respond to food. Since drugs like semaglutide (Ozempic) and tirzepatide mimic GLP-1, they likely produce similar effects on the brain — reducing the pull toward food rather than just making you feel physically full.
Is gastric bypass effective mainly because it makes the stomach smaller?
This study suggests it's more complex than that. While the smaller stomach plays a role, the surgery also dramatically increases GLP-1 production, which changes how the brain processes food rewards. When researchers blocked GLP-1 after surgery, the brain's heightened food responses came back, suggesting the hormonal changes are a major driver of the surgery's success.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-03494APA
Ten Kulve, Jennifer S; Veltman, Dick J; Gerdes, Victor E A; van Bloemendaal, Liselotte; Barkhof, Frederik; Deacon, Carolyn F; Holst, Jens J; Drent, Madeleine L; Diamant, Michaela; IJzerman, Richard G. (2017). Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.. Diabetes care, 40(11), 1522-1529. https://doi.org/10.2337/dc16-2113
MLA
Ten Kulve, Jennifer S, et al. "Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.." Diabetes care, 2017. https://doi.org/10.2337/dc16-2113
RethinkPeptides
RethinkPeptides Research Database. "Elevated Postoperative Endogenous GLP-1 Levels Mediate Effec..." RPEP-03494. Retrieved from https://rethinkpeptides.com/research/ten-2017-elevated-postoperative-endogenous-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.